Comparing Postprandial Glycemic Control Using Fiasp vs Insulin Aspart in Hospitalized Patients With Type 2 Diabetes
Authors' conclusion
Fiasp provides noninferior postprandial glucose control in hospitalized patients with type 2 diabetes when compared to Novolog with no increase in rates of hypoglycemia.
Study context
- Population
- Noncritically ill hospitalized patients with T2D in a non-ICU setting, safety-net hospital106 analysed
- Participants
- 137 participants
- Comparison
- Fiasp vs insulin aspart as part of basal-bolus regimen
- Primary endpoint
- Time in sensor glucose range 100-180 mg/dL in the 4-hour postprandial period (blinded Dexcom G6 Pro)
- Follow-up
- 4-hour postprandial period
Methodological detailsprospective, open-label, noninferiority
- Prospective
- Open-label
- Noninferiority
Primary result
As reported in the abstract
4-hour postprandial time in range 100-180 mg/dL
P = 0.012
Further findings
- Other glycemic metrics were similar between groups
Safety
Time in hypoglycemic ranges (<70, <54, <40 mg/dL)
- No difference in time spent in hypoglycemic ranges
Original publication
Comparing Postprandial Glycemic Control Using Fiasp vs Insulin Aspart in Hospitalized Patients With Type 2 Diabetes. Endocr Pract. Published 4 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →